Xenon Pharmaceuticals (XENE) Current Assets (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Current Assets data on file, last reported at $1.1 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $1.1 billion, up 95.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 95.68% YoY), and the FY2025 annual result was $560.6 million, down 11.75% from the prior year.
• Current Assets climbed to $1.1 billion in Q1 2026 per XENE's latest filing, from $560.6 million in the prior quarter.
• Over five years, Current Assets peaked at $1.1 billion in Q1 2026 and troughed at $480.1 million in Q3 2025.
• A 5-year average of $634.5 million and a median of $600.3 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2023: Current Assets jumped 197.95% in 2022, then slumped 31.48% in 2023.
• A 5-year view of Current Assets shows it stood at $600.3 million in 2022, then gained by 7.44% to $645.0 million in 2023, then slipped by 1.5% to $635.3 million in 2024, then dropped by 11.75% to $560.6 million in 2025, then soared by 97.38% to $1.1 billion in 2026.
• Business Quant data shows XENE's Current Assets at $1.1 billion in Q1 2026, $560.6 million in Q4 2025, and $480.1 million in Q3 2025.